Ascidian Therapeutics

Ascidian Therapeutics is a biotechnology company dedicated to advancing its platform for medical and clinical gene therapy while bolstering the development of other pipelines in ophthalmology, neurology, neuromuscular, and rare diseases. Ascidian is currently focused on advancing its lead program, the ABCA4 exon editor, into clinical trials to treat retinal diseases, including Stargardt disease (STGD1), which causes fundus flavimaculatus.